ClinicalTrials.gg
CompletedNCT05277922Updated Apr 23, 2025Results posted

Effect of C21 on Forearm Blood Flow

A Phase 1 interventional study of C21 and Sodium Nitroprusside in Study Vasodilatory Effects of C21, sponsored by Vicore Pharma AB. Completed at 1 site in Sweden. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-23.

Sponsored by Vicore Pharma AB · Phase 1, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to assess the effect of C21 on forearm blood flow by use of strain-gauge venous occlusion plethysmography.

Read the detailed description

Subject will be screened for eligibility. Eligible subjects will receive ascending doses of C21 (3, 10, 30, 100, and 200 µg/min through local intra-arterial infusions for 5 min/dose. Forearm blood flow measurements will be performed in both arms during the last 2 minutes of each dose.

Infusions of sodium nitroprusside will be performed as a positive control using the same methodology.

02

Conditions studied

  • Study Vasodilatory Effects of C21
03

In context

Lead sponsor

Vicore Pharma AB is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give written for participation in the study and to comply with study requirements.
  2. Healthy male subject aged 18-45 years
  3. ≥ 18.5 and ≤ 30.0 kg/m2.
  4. Wlling to use condom or be vasectomised or practice sexual abstinence
  5. Clinically normal medical history, physical findings, vital signs, and laboratory values

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder which may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  2. History of thrombotic disease, vascular disorder, or severe bleeding disease.
  3. Poor brachial artery access.
  4. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of baseline
  5. within the past 5 years with the exception of basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  6. Any planned major surgery within the duration of the study.
  7. Any positive result on screening for serum surface antigen, antibody and (HIV).
  8. Abnormal vital signs
  9. Prolonged , cardiac arrhythmias or any clinically significant abnormalities in the resting
  10. History of severe allergy/ or ongoing allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to the IMPs, including any of the of the IMPs.
  11. Regular use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins, and minerals
  12. Regular use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid
  13. Vaccination within 1 week prior to dosing or plans to receive any vaccine during the study conduct.
  14. Planned treatment or treatment with another drug within 3 months
  15. Current regular smokers or users of nicotine products.
  16. History of alcohol abuse
  17. Presence or history of drug abuse
  18. Positive screen for drugs of abuse or alcohol at screening
  19. History of, or current use of, anabolic steroids.
  20. Inability to refrain from consuming caffeine-containing beverages during Day 1
  21. Plasma donation within 1 month of screening or blood donation (or corresponding blood loss) during the 3 months prior to screening.
  22. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    C21 combined

    15 µg C21 (infusion rate 3 µg/min) 50 µg C21 (infusion rate 10 µg/min) 150 µg C21 (infusion rate 30 µg/min) 500 µg C21 (infusion rate 100 µg/min) 1000 µg C21 (infusion rate 200 µg/min)

    Drug: C21

  • Experimental
    Positive control

    4 µg nitroprusside (infusion rate 0.8 µg/min) 8 µg nitroprusside (infusion rate 1.6 µg/min) 16 µg nitroprusside (infusion rate 3.2 µg/min)

    Drug: Sodium Nitroprusside

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intraarterial Doses of C21

    Percentage change from baseline in forearm blood flow (FBF) in response to increasing intraarterial doses of C21 (3, 10, 30, 100, and 200 μg/min)

    Time frame: 85 minutes

Secondary outcomes

  1. Dose-response Curve of C21 on Forearm Blood Flow (FBF)

    Geometric mean forearm blood flow (mL/min) by increasing C21 dose (3, 10, 30, 100, and 200 μg/min)

    Time frame: 85 min

  2. Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intra-arterial Doses of Sodium Nitroprusside

    Percentage change from baseline in forearm blood flow in response to increasing intra-arterial doses of sodium nitroprusside (0.8, 1.6, and 3.2 μg/min)

    Time frame: 45 minutes

  3. Frequency of Adverse Events

    Total number of adverse events was counted

    Time frame: Day 1-7

  4. Number of Mild, Moderate, and Severe Adverse Events

    Number of mild, moderate, and severe adverse events was counted

    Time frame: Day 1-7

  5. Number of Serious Adverse Events (SAEs)

    Number of serious adverse events (SAEs) was counted

    Time frame: Day 1-7

  6. Number of Participants With Clinically Significant Changes in Vital Sign Parameters

    Participants with Clinically significant changes from baseline (screening ) to the end of treatment in mean systolic blood pressure, diastolic blood pressure or pulse rate were counted

    Time frame: 5 hours

  7. Number of Participants With Clinically Significant Changes in ECG Parameters

    Participants with Clinically significant changes from baseline (screening ) to the end of treatment in mean values of the ECG parameters were counted

    Time frame: 5 hours

  8. Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters

    Participants with Clinically significant changes from baseline (screening ) to the end of treatment (Day 1) in mean clinical chemistry, haematology or coagulation parameters were counted

    Time frame: 5 hours

07

Results

Posted Apr 23, 2025

Participant flow

15 µg C21
Participant flow — 15 µg C21
MilestoneC21 CombinedPositive Control
Started50
Completed50
Not completed00
50 µg C21
Participant flow — 50 µg C21
MilestoneC21 CombinedPositive Control
Started50
Completed50
Not completed00
150 µg C21
Participant flow — 150 µg C21
MilestoneC21 CombinedPositive Control
Started50
Completed50
Not completed00
500 µg C21
Participant flow — 500 µg C21
MilestoneC21 CombinedPositive Control
Started50
Completed50
Not completed00
1000 µg C21
Participant flow — 1000 µg C21
MilestoneC21 CombinedPositive Control
Started50
Completed50
Not completed00
4 µg Nitroprusside
Participant flow — 4 µg Nitroprusside
MilestoneC21 CombinedPositive Control
Started05
Completed05
Not completed00
8 µg Nitroprusside
Participant flow — 8 µg Nitroprusside
MilestoneC21 CombinedPositive Control
Started05
Completed05
Not completed00
16 µg Nitroprusside
Participant flow — 16 µg Nitroprusside
MilestoneC21 CombinedPositive Control
Started05
Completed05
Not completed00

Outcome measures

PrimaryPercentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intraarterial Doses of C21

Percentage change from baseline in forearm blood flow (FBF) in response to increasing intraarterial doses of C21 (3, 10, 30, 100, and 200 μg/min)

Time frame:
85 minutes
Reported as:
Mean · percentage of change from baseline
Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intraarterial Doses of C21
percentage of change from baselineC21 3 ug/MinC21 10 ug/MinC21 30 ug/MinC21 100 ug/MinC21 200 ug/Min
Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intraarterial Doses of C2127.8 ± 24.317.2 ± 5.537.0 ± 26.628.5 ± 22.760.5 ± 38.3
SecondaryDose-response Curve of C21 on Forearm Blood Flow (FBF)

Geometric mean forearm blood flow (mL/min) by increasing C21 dose (3, 10, 30, 100, and 200 μg/min)

Time frame:
85 min
Reported as:
Geometric mean · mL/min
Dose-response Curve of C21 on Forearm Blood Flow (FBF)
mL/minC21 3 ug/MinC21 10 ug/MinC21 30 ug/MinC21 100 ug/MinC21 200 ug/Min
Dose-response Curve of C21 on Forearm Blood Flow (FBF)2.594 ± 43.22.594 ± 32.43.231 ± 44.73.215 ± 38.13.907 ± 24.5
Statistical analysis
  • C21 3 ug/Min vs C21 10 ug/Min · Geometric mean ratio: 0.9999 · 95% CI 0.8313 to 1.2025
  • C21 3 ug/Min vs C21 30 ug/Min · Geometric mean ratio: 1.2454 · 95% CI 1.0355 to 1.4979
  • C21 3 ug/Min vs C21 100 ug/Min · Geometric mean ratio: 1.2392 · 95% CI 1.0304 to 1.4904
  • C21 10 ug/Min vs C21 100 ug/Min · Geometric mean ratio: 1.2394 · 95% CI 1.0305 to 1.4906
  • C21 30 ug/Min vs C21 100 ug/Min · Geometric mean ratio: 0.9950 · 95% CI 0.8273 to 1.1967
  • C21 3 ug/Min vs C21 200 ug/Min · Geometric mean ratio: 1.5058 · 95% CI 1.2520 to 1.8110
  • C21 10 ug/Min vs C21 200 ug/Min · Geometric mean ratio: 1.5060 · 95% CI 1.2522 to 1.8113
  • C21 30 ug/Min vs C21 200 ug/Min · Geometric mean ratio: 1.2091 · 95% CI 1.0053 to 1.4541
  • C21 100 ug/Min vs C21 200 ug/Min · Geometric mean ratio: 1.2151 · 95% CI 1.0103 to 1.4614
  • C21 10 ug/Min vs C21 30 ug/Min · Geometric mean ratio: 1.2456 · 95% CI 1.0357 to 1.4981
SecondaryPercentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intra-arterial Doses of Sodium Nitroprusside

Percentage change from baseline in forearm blood flow in response to increasing intra-arterial doses of sodium nitroprusside (0.8, 1.6, and 3.2 μg/min)

Time frame:
45 minutes
Reported as:
Mean · percentage of change from baseline
Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intra-arterial Doses of Sodium Nitroprusside
percentage of change from baselineNipruss 0.8 ug/MinNipruss 1.6 ug/MinNipruss 3.2 ug/Min
Percentage Change From Baseline in Forearm Blood Flow in Response to Increasing Intra-arterial Doses of Sodium Nitroprusside319.8 ± 186.0229.5 ± 73.1319.6 ± 141.4
SecondaryFrequency of Adverse Events

Total number of adverse events was counted

Time frame:
Day 1-7
Reported as:
Number · Number of adverse events
Frequency of Adverse Events
Number of adverse eventsC21 GroupTotal
Frequency of Adverse Events33
SecondaryNumber of Mild, Moderate, and Severe Adverse Events

Number of mild, moderate, and severe adverse events was counted

Time frame:
Day 1-7
Reported as:
Number · Number of events
Number of Mild, Moderate, and Severe Adverse Events
Number of eventsC21 GroupTotal
Number of mild AEs33
Number of moderate Aes00
Number of severe AEs00
SecondaryNumber of Serious Adverse Events (SAEs)

Number of serious adverse events (SAEs) was counted

Time frame:
Day 1-7
Reported as:
Number · Number of SAEs
Number of Serious Adverse Events (SAEs)
Number of SAEsC21 GroupTotal
Number of Serious Adverse Events (SAEs)00
SecondaryNumber of Participants With Clinically Significant Changes in Vital Sign Parameters

Participants with Clinically significant changes from baseline (screening ) to the end of treatment in mean systolic blood pressure, diastolic blood pressure or pulse rate were counted

Time frame:
5 hours
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Sign Parameters
ParticipantsC21 GroupTotal
Number of Participants With Clinically Significant Changes in Vital Sign Parameters00
SecondaryNumber of Participants With Clinically Significant Changes in ECG Parameters

Participants with Clinically significant changes from baseline (screening ) to the end of treatment in mean values of the ECG parameters were counted

Time frame:
5 hours
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in ECG Parameters
ParticipantsC21 GroupTotal
Number of Participants With Clinically Significant Changes in ECG Parameters00
SecondaryNumber of Participants With Clinically Significant Changes in Safety Laboratory Parameters

Participants with Clinically significant changes from baseline (screening ) to the end of treatment (Day 1) in mean clinical chemistry, haematology or coagulation parameters were counted

Time frame:
5 hours
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters
ParticipantsC21 GroupTotal
Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters00

Adverse events

Collected over Adverse events were recorded from trial start until end-of-trial contact (follow-up), 7 days after trial start. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
C21 Group0/5 (0%)0/5 (0%)2/5 (40%)
Total0/5 (0%)0/5 (0%)2/5 (40%)
Most frequent other events
Most frequent other events
EventC21 GroupTotal
Infusion site bruisingGeneral disorders1/51/5
Ligament sprainInjury, poisoning and procedural complications1/51/5
PresyncopeNervous system disorders1/51/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)C21 Combined
Mean29.0 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)C21 Combined
Female0
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)C21 Combined
Hispanic or Latino0
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)C21 Combined
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White4
More than one race0
Unknown or Not Reported0
Height
Height(cm)C21 Combined
Mean180.0 ± 7.1
Weight
Weight(kg)C21 Combined
Mean86.8 ± 9.1
Body mass index
Body mass index(kg/m2)C21 Combined
Mean26.8 ± 2.8
08

Study locations

1 site
  • Clinical Trial Consultants AB
    Uppsala, Uppsala Lân 75237, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in May 2022, 0 months.

Results were first posted in Apr 2025, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2022
First posted
Mar 14, 2022
StartActual
Apr 28, 2022
Primary completionActual
May 11, 2022
CompletionActual
May 18, 2022
Results first posted
Apr 23, 2025
Last update
Apr 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05277922
Lead sponsor
Vicore Pharma AB
Collaborators
CTC Clinical Trial Consultants AB
Responsible party
Sponsor
First posted
Mar 14, 2022
Start date
Apr 28, 2022
Primary completion
May 11, 2022
Completion
May 18, 2022
Results posted
Apr 23, 2025
Last update
Apr 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Compound 21 · Nitroprusside

Start the discussion